- Home
- SPH vs TVTX Comparison
SPH vs TVTX Comparison
Compare SPH & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPH
- TVTX
- Stock Information
- Founded
- SPH 1945
- TVTX 2008
- Country
- SPH United States
- TVTX United States
- Employees
- SPH N/A
- TVTX N/A
- Industry
- SPH Other Specialty Stores
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- SPH Consumer Discretionary
- TVTX Health Care
- Exchange
- SPH Nasdaq
- TVTX Nasdaq
- Market Cap
- SPH 1.2B
- TVTX 1.4B
- IPO Year
- SPH 1996
- TVTX N/A
- Fundamental
- Price
- SPH $18.48
- TVTX $16.48
- Analyst Decision
- SPH Sell
- TVTX Strong Buy
- Analyst Count
- SPH 1
- TVTX 16
- Target Price
- SPH $17.00
- TVTX $33.33
- AVG Volume (30 Days)
- SPH 182.3K
- TVTX 1.5M
- Earning Date
- SPH 08-07-2025
- TVTX 07-31-2025
- Dividend Yield
- SPH 6.98%
- TVTX N/A
- EPS Growth
- SPH N/A
- TVTX N/A
- EPS
- SPH 1.46
- TVTX N/A
- Revenue
- SPH $1,424,243,000.00
- TVTX $273,533,000.00
- Revenue This Year
- SPH $10.99
- TVTX $73.84
- Revenue Next Year
- SPH N/A
- TVTX $46.72
- P/E Ratio
- SPH $12.76
- TVTX N/A
- Revenue Growth
- SPH 4.02
- TVTX 75.65
- 52 Week Low
- SPH $15.20
- TVTX $7.93
- 52 Week High
- SPH $22.24
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- SPH 48.05
- TVTX 59.73
- Support Level
- SPH $18.05
- TVTX $14.44
- Resistance Level
- SPH $18.71
- TVTX $16.64
- Average True Range (ATR)
- SPH 0.45
- TVTX 0.61
- MACD
- SPH 0.03
- TVTX 0.31
- Stochastic Oscillator
- SPH 39.94
- TVTX 94.18
About SPH Suburban Propane Partners L.P.
Suburban Propane Partners LP distributes propane, fuel oil, and other refined fuels to customers in the East Coast and West Coast regions of the United States. Other operations include natural gas and electricity marketing in the deregulated New York and Pennsylvania markets. The company operates in three segments: Propane; Fuel Oil and Refined Fuels; and Natural Gas and Electricity. It generates maximum revenue from Propane segment.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.